Alphagan P : Patient - About Glaucoma

What is Glaucoma?

Glaucoma is a group of diseases that can damage the eye's optic nerve and result in vision loss and blindness. Approximately 2.2 million Americans have been diagnosed with glaucoma.¹ It is typically characterized by elevated pressure inside the eye. This intraocular pressure (IOP) can damage the optic nerve and lead to permanent vision loss. While glaucoma is a lifelong condition, lowering IOP with daily treatment can prevent further vision loss.

ALPHAGAN^® P ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Important Safety Information
ALPHAGAN^® P (brimonidine tartrate ophthalmic solution) 0.1% should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, ocular redness, and itching. Adverse events occurring in approximately 5% to 9% included: burning sensation, increased ocular lymph nodules, increased ocular pressure, ocular allergic reaction, dry mouth, and blurred vision.

Please click here for full Prescribing Information.

^{1. More Americans facing blindness than ever before [press release]. National Eye Institute Web Site. Available at: http://www.nei.nih.gov/news/pressreleases/032002.asp. Accessed May 8, 2006.}